Non-specific and paradoxical effects of neo-adjuvant PS341 after radical prostatectomy in high-risk patients

被引：0
|
作者：
Ayala, G [1 ]
Li, R [1 ]
Thompson, TC [1 ]
Lynch, GR [1 ]
Mims, MP [1 ]
Frolov, A [1 ]
Hayes, T [1 ]
Wheeler, T [1 ]
Miles, BJ [1 ]
Kadmon, D [1 ]
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
来源：
LABORATORY INVESTIGATION | 2006年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
588
引用
收藏
页码：129A / 129A
页数：1
相关论文
共 50 条
  • [21] Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer
    Ravi, Praful
    Kwak, Lucia
    Devlies, Wout
    Xie, Wanling
    Chipidza, Fallon
    Yang, Xiaoyu
    Bubley, Glenn
    Kaplan, Irving
    Kibel, Adam S.
    Nguyen, Paul
    Taplin, Mary-Ellen
    PROSTATE, 2024, 84 (04): : 342 - 348
  • [22] Adjuvant enzalutamide (Enza) for men with high-risk prostate cancer (HRPCa) after radical prostatectomy (RP).
    Ornstein, Moshe Chaim
    Stephenson, Andrew J.
    Elson, Paul
    Tyler, Allison Janine
    Profusek, Pam
    Grivas, Petros
    Rini, Brian I.
    Klein, Eric A.
    Garcia, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Early postoperative Radiotherapy after radical Prostatectomy in High-risk Prostate Cancer Patients
    Ehmann, M.
    Wenz, F.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2013, 189 (05) : 431 - 432
  • [24] Adjuvant vs. salvage radiotherapy for patients at high risk for recurrence after radical prostatectomy
    Falchook, Aaron D.
    Chen, Ronald C.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (11) : 451 - 455
  • [25] Revision of: a phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma
    van Meekeren, Milan
    Bovee, Judith V. M. G.
    van Coevorden, Frits
    van Houdt, Winan
    Schrage, Yvonne
    Koenen, Anne Miek
    Miah, Aisha B.
    Zaidi, Shane
    Hayes, Andrew J.
    Thway, Khin
    Krol, Stijn
    Fiocco, Marta
    Gelderblom, Hans
    Steeghs, Neeltje
    Haas, Rick L.
    ACTA ONCOLOGICA, 2021, 60 (12) : 1557 - 1564
  • [26] Metastatic Disease Response and Patterns of Recurrence in Men with High-Risk Prostate Cancer after Neo-Adjuvant Chemohormonal Therapy and Radical Prostatectomy utilizing PSMA-Targeted 18F-DCFPyL PET/CT
    Lovrec, Petra
    Belson, Patrick
    Wells, Shane
    Kyriakopoulos, Christos
    Huang, Wei
    Beebe, David
    Lang, Joshua
    Jarrard, David
    Cho, Steve
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [27] COST-EFFECTIVENESS ANALYSIS OF ADJUVANT VERSUS SALVAGE RADIOTHERAPY AFTER RADICAL PROSTATECTOMY FOR HIGH-RISK DISEASE
    Daily, Ellen
    Park, Sangtae
    JOURNAL OF UROLOGY, 2016, 195 (04): : E148 - E148
  • [28] RADIOTHERAPY STRATEGY AFTER RADICAL PROSTATECTOMY: SALVAGE RADIOTHERAPY UPON PSA RECURRENCE MAY BE PREFERABLE TO ADJUVANT RADIOTHERAPY FOR HIGH-RISK PATIENTS
    Cremers, R. G. H. M.
    Van Oort, I. M.
    Hulsbergen-V. D. Kaa, C. A.
    Van Lin, E. N. J. T.
    Witjes, J. A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 207 - 207
  • [29] Pilot trial of adjuvant paclitaxel (T) and estramustine phosphate (EMP) for high-risk prostate cancer patients after radical prostatectomy (RP).
    Lubiniecki, GM
    Malkowicz, SB
    Hendricks, M
    Bearn-Miranda, L
    van Arsdalen, K
    Wein, A
    Vaughn, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 446S - 446S
  • [30] Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients
    Hoeh, Benedikt
    Wuernschimmel, Christoph
    Flammia, Rocco S.
    Horlemann, Benedikt
    Sorce, Gabriele
    Chierigo, Francesco
    Tian, Zhe
    Saad, Fred
    Graefen, Markus
    Gallucci, Michele
    Briganti, Alberto
    Terrone, Carlo
    Shariat, Shahrokh F.
    Kluth, Luis A.
    Mandel, Philipp
    Chun, Felix K. H.
    Karakiewicz, Pierre, I
    PROSTATE, 2022, 82 (01): : 120 - 131
12345